MedTrace Logo

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

NCT06383572 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-12-23

No results posted yet for this study

Summary

To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.

Conditions

  • Lymphodepleting Chemotherapy
  • Myeloid Malignancies

Interventions

DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine phosphate

Given by IV

DRUG

Decitabine

Given by IV

DRUG

Dexamethasone

Given by mouth

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jeremy Ramdial, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-26
Primary Completion
2027-04-01
Completion
2029-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06383572 on ClinicalTrials.gov